文献速递类风湿关节炎

白细胞介素-6与其可溶性受体的联合水平与类风湿关节炎患者对托珠单抗治疗的应答相关

The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
PubMed 文献 · Semin Arthritis Rheum · 2017-11-20

研究纳入63例类风湿关节炎患者,于治疗前及治疗后3、6个月采集肝素化血及临床数据,用两步聚类法按基线血清IL-6与可溶性IL-6受体(sIL-6R)水平分组并比较EULAR应答与缓解情况。结果显示三个聚类组间6个月EULAR应答(p=0.03)与缓解获得(p=0.04)存在差异,g1组18例中17例获良好或中度应答,g3组无应答比例高于g1和g2。

要点

  • 基线IL-6与sIL-6R水平可将RA患者分为三个聚类组,各组间6个月EULAR应答与缓解获得存在差异。
  • g1组18例中17例对托珠单抗达良好或中度应答,g3组无应答比例高于g1和g2。
  • g3组病程最长,中位病程23(16-26)年,病程与sIL-6R水平相关(R=0.417,p<0.001)。

核心结论

  • RA患者可在治疗干预前用与托珠单抗所阻断通路相关的两个分子进行简便分层,g1组对托珠单抗应答最佳,其IL-6水平最高而sIL-6R水平最低。

研究设计与样本

  • 研究收集63例RA患者治疗前及治疗后3个月和6个月的肝素化血与临床数据,采用SPSS v.18两步聚类法建立IL-6与sIL-6R的关系,并比较各患者组的EULAR应答标准与缓解获得情况。

主要发现

  • 基线血清IL-6与sIL-6R浓度定义出三个有统计学意义的聚类组(g1、g2、g3),所有组RA患者的IL-6与sIL-6R水平均高于健康供者。
  • IL-6水平以中位数(IQR)表示:g1为124(90-183)pg/ml,g2为12.3(4.4-24)pg/ml,g3为60.1(30-146)pg/ml(p<0.001)。
  • sIL-6R水平以均值±标准差表示:g1为250.5±72ng/ml,g2为269.1±125ng/ml,g3为732.7±243ng/ml(p<0.001)。
  • 三组基线DAS28、C反应蛋白和红细胞沉降率相当;g3组病程最长,中位(IQR)年数g1=11(5-15)、g2=12(8-20)、g3=23(16-26)(p=0.006),病程年数与sIL-6R水平相关(R=0.417,p<0.001)。
  • 三组SDAI与CDAI均显著下降,但6个月时EULAR应答标准与缓解获得在三组间不同(分别为p=0.03和p=0.04);g1组18例中17例对托珠单抗达良好或中度应答,g3组无应答患者百分比高于g1和g2,三组IL-6与sIL-6R水平变化模式亦不同。

关键数值与推荐

  • 以基线IL-6与sIL-6R血清浓度进行两步聚类,得到三个有统计学意义的聚类组g1、g2、g3。
  • 6个月时EULAR应答标准在三组间差异p=0.03,缓解获得在三组间差异p=0.04。
  • g1组18例中17例达良好或中度应答;g3组无应答患者百分比高于g1和g2(原文未报告具体百分比数值)。

临床怎么用

  • 原文结论认为RA患者可在治疗干预前用IL-6与sIL-6R这两个与托珠单抗阻断通路相关的分子进行简便分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IL-6 contributes significantly to the chronic inflammatory process of rheumatoid arthritis (RA). Tocilizumab, a humanized anti-human IL-6 receptor antibody that blocks the signaling originated by the IL-6/IL-6R complex, is an effective treatment. However, predictors of the response to tocilizumab are still required. We aimed to combine IL-6 and soluble IL-6R (sIL-6R) levels to identify groups of responses. METHODS: Heparinized blood and clinical data from 63 RA patients were collected before treatment and after 3 and 6 months. Two-step clustering (SPSS v.18) was used to establish the relationship between IL-6 and sIL-6R. Then, we compared European League Against Rheumatism (EULAR) response criteria with remission achievement in the groups of patients. RESULTS: Three statistical significant clusters of RA patients (i.e., g1, g2, and g3) were defined by serum concentrations of IL-6 and sIL-6R at baseline. All groups of RA patients had higher IL-6 and sIL-6R levels than healthy donors. The levels of IL-6 expressed as median (IQR) in g1 patients were 124(90-183)pg/ml, in g2 12.3(4.4-24)pg/ml, and in g3 60.1(30-146)pg/ml (p < 0.001). The levels of sIL-6R expressed as mean ± sd in g1 patients were 250.5 ± 72ng/ml, in g2 269.1 ± 125ng/ml, and in g3 732.7 ± 243ng/ml (p < 0.001). Disease activity score (DAS)28, C-reactive protein, and erythrocyte sedimentation rate were comparable in the three groups at baseline. Disease duration in g3 was the longest (median(IQR) years: g1 = 11(5-15), g2 = 12(8-20), and g3 23(16-26); p = 0.006), with years of disease evolution being correlated with sIL-6R levels (R = 0.417, p < 0.001). Simple and Clinical Disease Activity Index (SDAI and CDAI) decreased significantly in the three groups. However, EULAR response criteria and remission achievement at 6m was different in the three groups (p = 0.03 and 0.04, respectively). In all. 17 out of the 18 patients in g1 had a good or moderate response to tocilizumab. Conversely, the percentage of patients with no response to tocilizumab was higher in g3 than in g1 and g2. We also observed different changing patterns of IL-6 and sIL-6R levels among the three groups. CONCLUSIONS: RA patients could be easily stratified prior to therapeutic intervention with two molecules related to the pathway blocked by tocilizumab. G1 patients, who had the best response to tocilizumab, had the highest level of IL-6 and the lowest level of sIL-6R.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Diaz-Torne C, Ortiz MDA, Moya P, et al. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. Semin Arthritis Rheum. 2017. PMID: 29157669. doi:10.1016/j.semarthrit.2017.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。